TSHA Earnings & Financial Statements
Taysha Gene Therapies, Inc.
$4.50
+$0.07(+1.47%)
44
Overall
55
Value
27
Tech
50
Quality
Market Cap
$1.44B
Volume
1.68M
52W Range
$3.69 - $7.30
Target Price
$13.00
TSHA earnings and financial statements: Taysha Gene Therapies, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TSHA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | - |
| Operating income | -$110.50M | -$91.46M | -$72.44M | -$162.45M | -$173.27M |
| EBITDA | -$106.43M | -$86.73M | -$104.11M | -$161.04M | -$172.60M |
| Net income | -$109.00M | -$89.30M | -$111.57M | -$166.01M | -$174.52M |
| EPS (diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $343.32M | $160.36M | $172.73M | $126.28M | $213.96M |
| Total liabilities | $96.38M | $88.84M | $97.79M | $125.33M | $118.57M |
| Shareholders’ equity | $246.94M | $71.53M | $74.94M | $949.0K | $95.38M |
| Cash and equivalents | $319.80M | $139.04M | $143.94M | $87.88M | $149.10M |
| Long-term debt | $68.28M | $61.30M | $59.46M | $58.41M | $37.19M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$93.09M | -$81.22M | -$73.02M | -$88.39M | -$117.04M |
| Capital expenditure | -$738.0K | -$374.0K | -$7.37M | -$24.87M | -$21.55M |
| Free cash flow | -$93.83M | -$81.60M | -$80.39M | -$113.26M | -$138.60M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TSHA | $4.50 | +1.5% | 1.68M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Taysha Gene Therapies, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW